242 related articles for article (PubMed ID: 31879528)
1. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy.
Rodell CB; Ahmed MS; Garris CS; Pittet MJ; Weissleder R
Theranostics; 2019; 9(26):8426-8436. PubMed ID: 31879528
[TBL] [Abstract][Full Text] [Related]
2. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.
Rodell CB; Arlauckas SP; Cuccarese MF; Garris CS; Li R; Ahmed MS; Kohler RH; Pittet MJ; Weissleder R
Nat Biomed Eng; 2018 Aug; 2(8):578-588. PubMed ID: 31015631
[TBL] [Abstract][Full Text] [Related]
3. Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy.
Shang T; Yu X; Gu Y; Du R; Cai Y; Li Y; Zheng G; Wang C; Zhang J; Liu J; Han S; Yang B
Int J Biol Macromol; 2023 Nov; 251():126539. PubMed ID: 37634787
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.
Anfray C; Mainini F; Digifico E; Maeda A; Sironi M; Erreni M; Anselmo A; Ummarino A; Gandoy S; Expósito F; Redrado M; Serrano D; Calvo A; Martens M; Bravo S; Mantovani A; Allavena P; Andón FT
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531246
[TBL] [Abstract][Full Text] [Related]
5. Self-Assembled Nanoparticles from the Amphiphilic Prodrug of Resiquimod for Improved Cancer Immunotherapy.
Li JX; Shu N; Zhang YJ; Tong QS; Wang L; Zhang JY; Du JZ
ACS Appl Mater Interfaces; 2024 May; 16(20):25665-25675. PubMed ID: 38735053
[TBL] [Abstract][Full Text] [Related]
6. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
8. Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator.
Lu R; Groer C; Kleindl PA; Moulder KR; Huang A; Hunt JR; Cai S; Aires DJ; Berkland C; Forrest ML
J Control Release; 2019 Jul; 306():165-176. PubMed ID: 31173789
[TBL] [Abstract][Full Text] [Related]
9. Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors.
Anfray C; Varela CF; Ummarino A; Maeda A; Sironi M; Gandoy S; Brea J; Loza MI; León S; Calvo A; Correa J; Fernandez-Megia E; Alonso MJ; Allavena P; Crecente-Campo J; Andón FT
Front Immunol; 2023; 14():1334800. PubMed ID: 38259462
[TBL] [Abstract][Full Text] [Related]
10. Host-functionalization of macrin nanoparticles to enable drug loading and control tumor-associated macrophage phenotype.
Sarkar B; Arlauckas SP; Cuccarese MF; Garris CS; Weissleder R; Rodell CB
Front Immunol; 2024; 15():1331480. PubMed ID: 38545103
[TBL] [Abstract][Full Text] [Related]
11. Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study.
Thauvin C; Widmer J; Mottas I; Hocevar S; Allémann E; Bourquin C; Delie F
Eur J Pharm Biopharm; 2019 Jun; 139():253-261. PubMed ID: 30981947
[TBL] [Abstract][Full Text] [Related]
12. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
[TBL] [Abstract][Full Text] [Related]
13. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
[TBL] [Abstract][Full Text] [Related]
14. Supramolecular Lipid Nanoparticles Based on Host-Guest Recognition: A New Generation Delivery System of mRNA Vaccines For Cancer Immunotherapy.
Qi S; Zhang X; Yu X; Jin L; Yang K; Wang Y; Feng Y; Lei J; Mao Z; Yu G
Adv Mater; 2024 Jun; 36(23):e2311574. PubMed ID: 38433564
[TBL] [Abstract][Full Text] [Related]
15. T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles.
Turco V; Pfleiderer K; Hunger J; Horvat NK; Karimian-Jazi K; Schregel K; Fischer M; Brugnara G; Jähne K; Sturm V; Streibel Y; Nguyen D; Altamura S; Agardy DA; Soni SS; Alsasa A; Bunse T; Schlesner M; Muckenthaler MU; Weissleder R; Wick W; Heiland S; Vollmuth P; Bendszus M; Rodell CB; Breckwoldt MO; Platten M
Nat Commun; 2023 Feb; 14(1):771. PubMed ID: 36774352
[TBL] [Abstract][Full Text] [Related]
16. Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment.
Kang Y; Flores L; Ngai HW; Cornejo YR; Haber T; McDonald M; Moreira DF; Gonzaga JM; Abidi W; Zhang Y; Hammad M; Kortylewski M; Aboody KS; Berlin JM
Bioconjug Chem; 2021 Aug; 32(8):1581-1592. PubMed ID: 34289694
[TBL] [Abstract][Full Text] [Related]
17. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells.
Lee M; Park CS; Lee YR; Im SA; Song S; Lee CK
Arch Pharm Res; 2014; 37(9):1234-40. PubMed ID: 24748512
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
19. TLR7 and TLR8 agonist resiquimod (R848) differently regulates MIF expression in cells and organs.
Adzavon YM; Zhao P; Lv B; Liu M; Zhang X; Xie F; Yang L; Shang L; Zhang M; Li Q; Ma X
Cytokine; 2017 Sep; 97():156-166. PubMed ID: 28648870
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional nanoparticles based on a polymeric copper chelator for combination treatment of metastatic breast cancer.
Zhou P; Qin J; Zhou C; Wan G; Liu Y; Zhang M; Yang X; Zhang N; Wang Y
Biomaterials; 2019 Mar; 195():86-99. PubMed ID: 30623789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
